Krakauer R S, Strober W, Waldmann T A
J Immunol. 1977 Apr;118(4):1385-90.
We have investigated the pathogenesis of the polyclonal hypogammaglobulinemia associated with BALB/c plasmacytomas TEPC-183 and SPQC-11 to gain insight into the hypogammaglobulinemia observed in human myeloma. With pokeweed mitogen-driven IgM biosynthesis by mouse splenocytes as the indicator system for suppression, we found that a protein extract of asscites cells obtained from these tumor-bearing animals could suppress immunoglobulin production, whereas like extracts from a non-suppressing plasmacytoma, modified RPC-5, caused no suppression in vitro. Extracts of tumor ascites depleted of mononuclear phagocytes by iron carbonyl treatment showed little suppressor activity. The active extract was not cytotoxic and contained no mycoplasma or common murine viruses. Furthermore, the active suppressor factor appears to be a low m.w. protein that is not affected by treatment with ribonuclease. These results and others are consistent with the idea that the hypogammaglobulinemia of myeloma is due to the formation of immunoregulatory macrophage-like cells which synthesize a suppressor substance.
我们研究了与BALB/c浆细胞瘤TEPC-183和SPQC-11相关的多克隆低丙种球蛋白血症的发病机制,以深入了解人类骨髓瘤中观察到的低丙种球蛋白血症。以美洲商陆有丝分裂原驱动的小鼠脾细胞IgM生物合成作为抑制的指示系统,我们发现从这些荷瘤动物获得的腹水细胞的蛋白质提取物可以抑制免疫球蛋白的产生,而来自非抑制性浆细胞瘤(改良的RPC-5)的类似提取物在体外没有抑制作用。经羰基铁处理耗尽单核吞噬细胞的肿瘤腹水提取物显示出很少的抑制活性。活性提取物无细胞毒性,且不含支原体或常见的鼠病毒。此外,活性抑制因子似乎是一种低分子量蛋白质,不受核糖核酸酶处理的影响。这些结果及其他结果与骨髓瘤低丙种球蛋白血症是由于形成了合成抑制物质的免疫调节性巨噬样细胞这一观点一致。